Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.

bioRxiv : the preprint server for biology·2026
Same author

Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI.

Blood advances·2026
Same author

Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation.

Transplantation and cellular therapy·2025
Same author

Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide.

Transplantation and cellular therapy·2025
Same author

Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2025

Related Experiment Video

Updated: Jul 2, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Chronic graft-versus-host disease.

Javier Bolaños-Meade1, Georgia B Vogelsang

  • 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Current Pharmaceutical Design
|August 12, 2008
PubMed
Summary

Chronic graft-versus-host disease (cGVHD) is a major complication after allogeneic bone marrow transplants, causing significant morbidity and mortality. New diagnostic criteria and therapies are improving outcomes for patients with steroid-refractory cGVHD.

More Related Videos

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
09:50

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice

Published on: February 11, 2019

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

Related Experiment Videos

Last Updated: Jul 2, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
09:50

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice

Published on: February 11, 2019

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Chronic graft-versus-host disease (cGVHD) is the most frequent late complication following allogeneic bone marrow transplantation.
  • It represents the primary cause of morbidity and mortality in long-term survivors.
  • Despite its impact, cGVHD remains understudied compared to its acute counterpart.

Purpose of the Study:

  • To summarize recent advancements in understanding and managing chronic graft-versus-host disease.
  • To highlight new diagnostic and staging criteria.
  • To discuss emerging therapeutic strategies for steroid-refractory cGVHD.

Main Methods:

  • Review of findings from the National Institutes of Health sponsored Chronic Graft-versus-Host Disease Consensus Conference.
  • Analysis of emerging research on cGVHD pathophysiology, including the role of B cells.
  • Evaluation of novel therapeutic agents and treatment modalities.

Main Results:

  • New consensus criteria for diagnosis, staging, pathology, biomarkers, response, and supportive care have been proposed.
  • Understanding the pathophysiology, particularly the role of B cells, is influencing treatment approaches.
  • Novel agents like pentostatin, mycophenolate mofetil, rituximab, and extracorporeal photochemotherapy show promise.

Conclusions:

  • Chronic graft-versus-host disease is a critical area requiring further research and clinical attention.
  • Updated diagnostic and staging criteria are essential for consistent patient management.
  • Novel therapeutic strategies are improving outcomes for patients with refractory cGVHD, offering new hope for long-term survivors.